

Contents

Preface — V

1 General aspects — 1

1.1 History — 1

1.1.1 From willow bark to salicylic acid — 9

1.1.1.1 Antiinflammatory and analgesic effects of willow bark — 9

1.1.1.2 Salicylates as the active ingredients of willow bark and other natural sources — 10

1.1.1.3 Chemical synthesis of salicylic acid — 10

1.1.2 Synthesis of acetylated salicylic acid (Aspirin) and first medical use — 13

1.1.2.1 The invention of acetylated salicylic acid — 13

1.1.2.2 Introduction of acetylsalicylic acid in the clinic — 20

1.1.3 Search for pharmacological modes of aspirin action — 23

1.1.3.1 Salicylates and energy metabolism of the cell — 24

1.1.3.2 Inhibition of cyclooxygenases by salicylates — 25

1.1.3.3 Further actions of salicylates on cell signaling — 30

1.1.4 Clinical applications – a piece of history — 34

1.1.4.1 Antiinflammatory/analgesic and antipyretic actions — 34

1.1.4.2 Antiplatelet/antithrombotic actions and bleeding — 35

1.1.4.3 Aspirin and the history of prevention of myocardial infarction and stroke — 37

1.1.4.4 Aspirin and tumor prevention — 41

1.1.5 Current research topics — 44

1.1.5.1 Clinical research — 44

1.1.5.2 Basic research — 45

1.2 Chemistry — 49

1.2.1 Structures and chemical properties of salicylates — 50

1.2.1.1 Salicylates in clinical use – chemical properties — 51

1.2.1.2 Aspirin formulations — 53

1.2.2 Determination of salicylates — 56

1.2.2.1 General aspects — 56

1.2.2.2 Methods of determination — 57

2 Pharmacology — 61

2.1 Pharmacokinetics — 62

2.1.1 Absorption and distribution — 63

2.1.1.1 Absorption and bioavailability — 63

2.1.1.2 Aspirin formulations and application modes — 66

2.1.1.3 Distribution and plasma levels — 71

2.1.1.4	Modifying factors — 73
2.1.2	Biotransformation and excretion — 77
2.1.2.1	Biotransformations of aspirin — 77
2.1.2.2	Biotransformations of salicylic acid — 81
2.1.2.3	Excretion of salicylates — 83
2.2	Cellular modes of action — 87
2.2.1	Inhibition of cyclooxygenases — 89
2.2.1.1	General aspects — 89
2.2.1.2	Inhibition/modulation of cyclooxygenases by aspirin — 91
2.2.1.3	The different pharmacology of aspirin and NSAIDs — 98
2.2.1.4	Further actions of salicylates on lipid mediators — 100
2.2.2	COX-independent actions of aspirin on cell function — 104
2.2.2.1	General aspects — 104
2.2.2.2	Salicylates in the plant kingdom — 105
2.2.2.3	Non-COX acetylation actions of aspirin — 106
2.2.2.4	Aspirin and nitric oxide formation — 106
2.2.2.5	Salicylates and kinases — 109
2.2.2.6	Salicylates and transcription factors — 113
2.2.3	Energy metabolism — 119
2.2.3.1	General aspects — 119
2.2.3.2	Salicylates and fatty acid β -oxidation — 121
2.2.3.3	Salicylates and uncoupling of oxidative phosphorylation — 125
2.2.3.4	Metabolic actions of salicylates and Reye's syndrome — 128
2.3	Actions on organs and tissues — 133
2.3.1	Hemostasis and thrombosis — 134
2.3.1.1	General aspects — 134
2.3.1.2	Platelets — 137
2.3.1.3	Endothelial cells — 145
2.3.1.4	Plasmatic coagulation — 150
2.3.1.5	Fibrinolysis — 150
2.3.2	Inflammation, microbial infections, pain and fever — 160
2.3.2.1	General aspects — 160
2.3.2.2	Modes of antiinflammatory actions of aspirin — 162
2.3.2.3	Modes of antimicrobial actions of aspirin — 170
2.3.2.4	Modes of analgesic actions of aspirin — 172
2.3.2.5	Modes of antipyretic actions of aspirin — 177
2.3.3	Aspirin and malignancies — 185
2.3.3.1	General aspects — 185
2.3.3.2	Pathophysiology of intestinal neoplasias — 187
2.3.3.3	Modes of aspirin action — 191
2.3.3.4	COX-related actions of aspirin — 192
2.3.3.5	Non-COX-related antitumor actions of aspirin — 196

3	Toxicity and drug safety — 207
3.1	Systemic side effects — 208
3.1.1	Acute and chronic toxicity — 209
3.1.1.1	General aspects — 209
3.1.1.2	Pathophysiology and clinical symptoms of acute toxicity — 211
3.1.1.3	Pathophysiology and clinical symptoms of chronic toxicity — 214
3.1.1.4	Treatment — 215
3.1.1.5	Habituation — 216
3.1.2	Bleeding time and bleeding risk — 221
3.1.2.1	General aspects — 221
3.1.2.2	Bleeding time — 221
3.1.2.3	Modes of aspirin action — 225
3.1.2.4	Aspirin-related bleeding in long-term prevention — 227
3.1.2.5	Aspirin-related bleeding in surgery and withdrawal — 228
3.1.2.6	Prevention and treatment of bleeding — 230
3.1.3	Safety pharmacology in particular life situations — 237
3.1.3.1	General aspects — 237
3.1.3.2	Pregnancy and fetal development — 237
3.1.3.3	The elderly patient — 241
3.2	Organ toxicity — 248
3.2.1	Gastrointestinal tract — 248
3.2.1.1	General aspects — 248
3.2.1.2	Pathophysiology of gastrointestinal (stomach) injury — 249
3.2.1.3	Modes of aspirin action — 252
3.2.1.4	Clinical studies — 258
3.2.1.5	Aspirin and other drugs — 262
3.2.2	Liver — 269
3.2.2.1	General aspects — 269
3.2.2.2	Pathophysiology and mode of aspirin action — 270
3.2.2.3	Clinical studies — 270
3.2.3	Kidney and heart failure — 273
3.2.3.1	General aspects — 273
3.2.3.2	Mode of aspirin action — 274
3.2.3.3	Clinical studies – individuals without kidney diseases — 275
3.2.3.4	Clinical studies – individuals with preexisting kidney diseases — 276
3.2.3.5	Heart failure — 279
3.2.4	Audiovestibular system — 284
3.2.4.1	General aspects — 284
3.2.4.2	Pathophysiology of aspirin-induced hearing loss — 285
3.2.4.3	Clinical studies — 287
3.3	Hypersensitivity to aspirin and Reye's syndrome — 291

3.3.1	Aspirin-exacerbated respiratory disease (“aspirin-induced asthma,” Widal syndrome) — 292
3.3.1.1	History and epidemiology — 292
3.3.1.2	Pathophysiology of AERD — 293
3.3.1.3	Mode of aspirin action — 297
3.3.1.4	Clinical studies — 299
3.3.1.5	Aspirin and other drugs — 301
3.3.2	Urticaria/angioedema, Stevens–Johnson syndrome and Lyell syndrome — 306
3.3.2.1	Urticaria/angioedema — 306
3.3.2.2	Stevens–Johnson syndrome and Lyell syndrome — 307
3.3.3	Reye’s syndrome — 309
3.3.3.1	History and epidemiology — 309
3.3.3.2	Clinics, laboratory and morphological findings — 311
3.3.3.3	Etiology and pathogenesis — 313
3.3.3.4	Clinical studies — 316
3.3.3.5	Actual situation — 323
4	Clinical applications of aspirin — 331
4.1	Thromboembolic diseases — 337
4.1.1	Coronary vascular disease — 338
4.1.1.1	General aspects — 338
4.1.1.2	Thrombotic risk and mode of aspirin action — 340
4.1.1.3	Clinical trials – primary prevention in apparently healthy individuals — 344
4.1.1.4	Clinical trials – primary prevention in individuals with vascular risk factors — 353
4.1.1.5	Clinical trials – primary prevention in patients with diabetes — 357
4.1.1.6	Clinical trials – patients with chronic coronary vascular disease — 362
4.1.1.7	Clinical trials – patients with acute coronary syndrome (ACS) — 363
4.1.1.8	Clinical trials – long-term secondary prevention — 367
4.1.1.9	Clinical trials – coronary artery bypass graft surgery and other surgical interventions — 373
4.1.1.10	Aspirin and other drugs — 376
4.1.1.11	Actual situation — 390
4.1.2	Cerebrovascular diseases — 409
4.1.2.1	General aspects — 409
4.1.2.2	Thrombotic risk and mode of aspirin action — 411
4.1.2.3	Clinical trials – primary prevention — 415
4.1.2.4	Clinical trials – secondary prevention — 416
4.1.2.5	Aspirin and other drugs — 424
4.1.2.6	Actual situation — 435

- 4.1.3 Peripheral arterial occlusive disease — **445**
- 4.1.3.1 General aspects — **445**
- 4.1.3.2 Thrombotic risk and mode of aspirin action — **447**
- 4.1.3.3 Clinical trials: primary prevention — **449**
- 4.1.3.4 Clinical trials: secondary prevention — **451**
- 4.1.3.5 Clinical trials: peripheral transluminal angioplasty — **452**
- 4.1.3.6 Aspirin and other drugs — **454**
- 4.1.3.7 Actual situation — **457**
- 4.1.4 Venous thromboembolism — **461**
- 4.1.4.1 General aspects — **461**
- 4.1.4.2 Thrombotic risk and modes of aspirin action — **464**
- 4.1.4.3 Clinical trials – primary prevention — **464**
- 4.1.4.4 Clinical trials – secondary prevention — **471**
- 4.1.4.5 Aspirin and other drugs – NOACs — **473**
- 4.1.4.6 Actual situation — **474**
- 4.1.5 Pregnancy-induced hypertension (preeclampsia) and preterm delivery — **479**
- 4.1.5.1 General aspects — **479**
- 4.1.5.2 Vascular risk and modes of aspirin action — **481**
- 4.1.5.3 Clinical trials — **486**
- 4.1.5.4 Clinical trials – reasons for data variability — **488**
- 4.1.5.5 Actual situation — **492**
- 4.1.6 Aspirin “high on treatment platelet reactivity” (HTPR, aspirin resistance) — **500**
- 4.1.6.1 General aspects — **500**
- 4.1.6.2 Definition and types of aspirin – HTPR — **501**
- 4.1.6.3 Detection of aspirin HTPR — **504**
- 4.1.6.4 Mechanisms of aspirin HTPR — **507**
- 4.1.6.5 Clinical trials — **515**
- 4.1.6.6 Actual situation — **519**
- 4.2 Pain, fever and inflammatory diseases — **528**
- 4.2.1 Analgesia and antipyresis — **529**
- 4.2.1.1 General aspects — **529**
- 4.2.1.2 Pain, fever and mode of analgesic/antipyretic aspirin action — **530**
- 4.2.1.3 Clinical trials — **534**
- 4.2.1.4 Aspirin and other drugs — **538**
- 4.2.1.5 Actual situation — **539**
- 4.2.2 Inflammatory diseases and viral infections — **542**
- 4.2.2.1 General aspects — **542**
- 4.2.2.2 Rheumatoid arthritis – pathophysiology, mode of aspirin action and clinical trials — **544**

4.2.2.3	Osteoarthritis – pathophysiology, mode of aspirin action and clinical trials —	547
4.2.2.4	Systemic inflammatory response syndrome (SIRS). Pathophysiology, mode of aspirin action and clinical trials. Sepsis and acute respiratory distress syndrome (ARDS) —	548
4.2.2.5	HIV – pathophysiology, mode of aspirin action and clinical trials —	552
4.2.2.6	COVID-19 and flu-like conditions: pathophysiology, modes of aspirin action and clinical trials —	555
4.2.2.7	Aspirin and other drugs —	559
4.2.2.8	Actual situation —	560
4.2.3	Kawasaki disease —	567
4.2.3.1	General aspects —	567
4.2.3.2	Pathophysiology and mode of aspirin action —	568
4.2.3.3	Clinical trials —	569
4.2.3.4	Aspirin and other drugs —	571
4.2.3.5	Actual situation —	571
4.3	Further potential clinical indications —	574
4.3.1	Colorectal tumors (adenomas, carcinomas) —	575
4.3.1.1	General aspects —	575
4.3.1.2	Epidemiology, etiology and pathogenesis —	576
4.3.1.3	Modes of aspirin action —	578
4.3.1.4	Clinical trials – primary prevention —	581
4.3.1.5	Clinical trials – secondary prevention —	587
4.3.1.6	Aspirin and other drugs —	593
4.3.1.7	Actual situation —	594
4.3.2	Alzheimer’s disease and other neurological disorders —	602
4.3.2.1	General aspects —	602
4.3.2.2	Epidemiology, etiology and pathophysiology —	602
4.3.2.3	Modes of aspirin action —	603
4.3.2.4	Clinical trials —	605
4.3.2.5	Aspirin and other drugs —	609
4.3.2.6	Actual situation —	609

Abbreviations — 613

Acronyms of clinical trials — 617

Index — 623